Background: Cognitive dysfunction is a frequent but under-recognized feature of fibromyalgia (FM). Its prevalence varies widely across studies, and independent clinical predictors remain uncertain. This study aimed to determine the prevalence of cognitive dysfunction in FM patients compared with healthy controls and identify independent associated factors. Methods: We conducted a case–control study including 47 adult female patients with FM (2016 ACR criteria) and 19 age- and sex-matched healthy controls. Sociodemographic and clinical data were collected. Cognitive function was evaluated using the Montreal Cognitive Assessment (MoCA), with cognitive dysfunction defined as MoCA < 26. Pain (VAS), fatigue (VAS and FACIT-F), anxiety and depression (HADS), sleep quality (PSQI), and disease impact (FIQ-P) were assessed. Univariate analysis was followed by binary logistic regression to identify independent predictors of cognitive dysfunction and multiple linear regression to explore associations with MoCA score. Results: Cognitive dysfunction was present in 72.3% of FM patients versus 5.3% of controls (p < 0.001). FM patients had significantly worse pain scores, fatigue levels, psychological distress, sleep quality, and quality of life (all p < 0.001). In FM patients, MoCA scores correlated inversely with pain (r = −0.34), anxiety (r = −0.34), depression (r = −0.48), disease impact (r = −0.43), and sleep disturbance (r = −0.48), and positively with FACIT-F (r = 0.37) and EQ-5D-5L (ρ = 0.60). In multivariate analysis, higher FIQ-P scores were independently associated with cognitive dysfunction [adjusted OR1.18; 95% CI (1.06–1.30); p < 0.01]. Pain severity [adjusted B = −0.40; 95%CI (−0.64–0.15; p < 0.01)] and depression [adjusted B = −2.60; 95% CI (−4.12–1.04; p = 0.001)] were independently associated with lower MoCA scores. Conclusions: Cognitive dysfunction is highly prevalent in FM and is independently associated with pain severity, depressive symptoms, and disease impact.
9 December 2023 in Rheumatology Advances in Practice
Dear Editor, axSpA has a predilection for the axial skeleton and belongs to the group of SpAs, a set of inflammatory rheumatic diseases with common clinical, radiologic and serologic features in which extra-articular manifestations are frequent, including IBD [ 1]. The link between SpA and IBD has been recognized for decades, with 6–14% of axSpA patients suffering from concurrent IBD [ 2, 3]. Emerging evidence suggests that subclinical gut inflammation in patients with SpA is an important pathophysiological event that plays a role in disease pathogenesis. However, it is difficult to detect subclinical gut inflammation since it is largely asymptomatic.
3 July 2024 in JCR: Journal of Clinical Rheumatology
Purpose: To evaluate two-year mortality predictors in all subtypes of fragility fractures. Methods: Medical records review, single-center study with Portuguese patients with fragility fractures; A univariate analysis, with chi-square for categorical variables and parametric t-student and non-parametric Wilcoxon tests for continuous variables, was performed. Posteriorly, a survival analysis, with subsequent Cox regression was conducted to establish independent risk factors/ predictors of two-year mortality in fragility fractures. Results: 758 patients were enrolled in the study. We found a total of 151 deaths within the first two years post-fracture. On Cox regression, older age [OR1.10 CI (1.05-1.11)], male sex [OR1.85 CI(1.24-2.75)], anemia at baseline [OR2.44 CI(1.67-3.57)], malignancy [OR4.68 CI (2.13-10.27)], and multimorbidity [OR1.78 CI(1.11-2.87)] were found as independent predictors for two-year post-fracture mortality. Conclusion: Our study suggests that male sex, older age, anemia, malignancy, and multimorbidity are mortality predictors in the first two years after fragility fractures, reinforcing the importance of comorbidity management in preventing or, at least, minimizing adverse outcomes following fragility fractures.